Medinotec Reports Strong YTD Revenue Growth and Significant Debt Reduction Amidst New US Tariff and Control Weakness

summarizeSummary

Medinotec Inc. reported strong year-to-date revenue growth of 41% and significantly reduced its related-party debt, while also securing FDA clearance for a new product. However, the company disclosed ineffective disclosure controls and highlighted risks from high customer concentration and a new U.S. tariff.

check_boxKey Events

• Strong Financial Performance

  For the nine months ended November 30, 2025, consolidated revenue increased by 41% to $7.9 million, with gross margin improving to 54% from 44% in the prior year. Net income rose by 26.6% to $863,761.

• Substantial Debt Repayment

  The company repaid substantially all outstanding related-party loans, reducing total loans payable from $940,277 as of February 28, 2025, to just $452 by November 30, 2025.

• New Product FDA Clearance

  The OutFlo Aortic Valve Dilatation Balloon Catheter received FDA 510(k) clearance on March 11, 2025, with a U.S. market launch planned for Q4 of the 2026 financial year.

• Disclosure Control Weakness Identified

  Management concluded that disclosure controls and procedures were not effective as of November 30, 2025, with remediation efforts expected to be completed by the end of fiscal year 2026.

auto_awesomeAnalysis

Medinotec Inc. delivered robust financial results for the nine months ended November 30, 2025, marked by substantial revenue growth and a significant reduction in outstanding debt. The company's gross margin also improved considerably, indicating enhanced operational efficiency. The FDA clearance for its OutFlo Aortic Valve Dilatation Balloon Catheter positions it for future growth in the U.S. market. However, these positives are tempered by critical risks, including a very high customer concentration, a newly imposed U.S. tariff on South African imports that will impact profitability, and a material weakness in disclosure controls. Investors should monitor the company's progress in mitigating these risks and its ability to execute its U.S. market expansion and uplisting plans.